Literature DB >> 16427342

Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors.

Sadagopan Magesh1, Tohru Suzuki, Taeko Miyagi, Hideharu Ishida, Makoto Kiso.   

Abstract

Four types of human sialidases have been cloned and characterized at the molecular level. They are classified according to their major intracellular location as intralysomal (NEU1), cytosolic (NEU2), plasma membrane (NEU3) and lysosomal or mitochondrial membrane (NEU4) associated sialidases. These human isoforms are distinct from each other in their enzymatic properties as well as their substrate specificity. Altered expression of sialidases has been correlated with malignant transformation of cells and different sialidases have been known to behave differently during carcinogenesis. Particularly, increased expression of NEU3 has been implicated in the survival of various cancer cells and also in the development of insulin resistance. In the present study, we have modeled three-dimensional structures of NEU1, NEU3 and NEU4 based on the crystal structure of NEU2 using the homology modeling program MODELER. The best model in each enzyme case was chosen on the basis of various standard protein analysis programs. Predicted structures and the experimental protein-ligand complex of NEU2 were compared to identify similarities and differences among the active sites. The molecular electrostatic potential (MEP) was calculated for the predicted models to identify the differences in charge distribution around the active site and its vicinity. The primary objective of the present work is to identify the structural differences between the different isoforms of human sialidases, namely NEU1, NEU2, NEU3 and NEU4, thus providing a better insight into the differences in the active sites of these enzymes. This can in turn guide us in the better understanding and rationale of the differential substrate recognition and activity, thereby aiding in the structure-based design of selective NEU3 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427342     DOI: 10.1016/j.jmgm.2005.12.006

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  16 in total

1.  Sialidase NEU3 is a peripheral membrane protein localized on the cell surface and in endosomal structures.

Authors:  Gabriele Zanchetti; Paolo Colombi; Marta Manzoni; Luigi Anastasia; Luigi Caimi; Giuseppe Borsani; Bruno Venerando; Guido Tettamanti; Augusto Preti; Eugenio Monti; Roberto Bresciani
Journal:  Biochem J       Date:  2007-12-01       Impact factor: 3.857

2.  Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies.

Authors:  Yanhong Li; Hongzhi Cao; Hai Yu; Yi Chen; Kam Lau; Jingyao Qu; Vireak Thon; Go Sugiarto; Xi Chen
Journal:  Mol Biosyst       Date:  2011-01-04

3.  Sialidases as regulators of bioengineered cellular surfaces.

Authors:  Cristina Y Zamora; Matthew J Ryan; Marc d'Alarcao; Krishna Kumar
Journal:  Glycobiology       Date:  2015-03-20       Impact factor: 4.313

4.  Desialylation of dying cells with catalytically active antibodies possessing sialidase activity facilitate their clearance by human macrophages.

Authors:  A Tomin; T Dumych; Y Tolstyak; I Kril; I Mahorivska; E Bila; R Stoika; M Herrmann; Y Kit; R Bilyy
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

5.  Developmental change of sialidase neu4 expression in murine brain and its involvement in the regulation of neuronal cell differentiation.

Authors:  Kazuhiro Shiozaki; Koichi Koseki; Kazunori Yamaguchi; Momo Shiozaki; Hisashi Narimatsu; Taeko Miyagi
Journal:  J Biol Chem       Date:  2009-06-08       Impact factor: 5.157

6.  Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.

Authors:  Aleksander Hinek; Tetyana D Bodnaruk; Severa Bunda; Yanting Wang; Kela Liu
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

7.  The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo.

Authors:  Sang W Hyun; Anguo Liu; Zhenguo Liu; Alan S Cross; Avelino C Verceles; Sadagopan Magesh; Yadagiri Kommagalla; Chandrababunaidu Kona; Hiromune Ando; Irina G Luzina; Sergei P Atamas; Kurt H Piepenbrink; Eric J Sundberg; Wei Guang; Hideharu Ishida; Erik P Lillehoj; Simeon E Goldblum
Journal:  Glycobiology       Date:  2016-05-25       Impact factor: 4.313

Review 8.  Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.

Authors:  Stephen Toovey; Craig Rayner; Eric Prinssen; Tom Chu; Barbara Donner; Bharat Thakrar; Regina Dutkowski; Gerhard Hoffmann; Alexander Breidenbach; Lothar Lindemann; Ellen Carey; Lauren Boak; Ronald Gieschke; Susan Sacks; Jonathan Solsky; Ian Small; David Reddy
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Inhibiting Sialidase-Induced TGF-β1 Activation Attenuates Pulmonary Fibrosis in Mice.

Authors:  Tejas R Karhadkar; Thomas D Meek; Richard H Gomer
Journal:  J Pharmacol Exp Ther       Date:  2020-11-03       Impact factor: 4.030

10.  Evaluation of a Set of C9 N-acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors.

Authors:  Sadagopan Magesh; Nongluk Sriwilaijaroen; Setsuko Moriya; Hiromune Ando; Taeko Miyagi; Yasuo Suzuki; Hideharu Ishida; Makoto Kiso
Journal:  Int J Med Chem       Date:  2010-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.